Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma

Journal of Immunotherapy

Volumn 36, Issue 8, 2013, Pages 442-450

  Creelan, Ben C ^a   Antonia, Scott ^b   Noyes, David ^b   Hunter, Terri B ^a   Simon, George R ^c   Bepler, Gerold ^d   Williams, Charles C ^b   Tanvetyanon, Tawee ^b   Haura, Eric B ^b   Schell, Michael J ^b   Chiappori, Alberto ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

Author keywords

adenocarcinoma; alltrans retinoic acid; bystander vaccine; CD40 ligand; CD40L; dendritic cell; GM CSF; non small cell lung cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; CANCER VACCINE; CD40 LIGAND; CYCLOPHOSPHAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RETINOIC ACID;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTHRALGIA; ARTICLE; BYSTANDER EFFECT; CANCER CELL CULTURE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CHILL; CYTOKINE PRODUCTION; DENDRITIC CELL; DIARRHEA; DISEASE ACTIVITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; FATIGUE; FEMALE; GENETIC TRANSFECTION; HEADACHE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INJECTION PAIN; INJECTION SITE REACTION; LEUKOPENIA; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; SIDE EFFECT; SYSTEMIC THERAPY; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TUMOR REGRESSION;

ADENOCARCINOMA; AGED; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; BYSTANDER EFFECT; CANCER VACCINES; CD40 LIGAND; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; DENDRITIC CELLS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; K562 CELLS; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RECURRENCE; SURVIVAL ANALYSIS; TRANSGENES; TREATMENT OUTCOME; TRETINOIN;

EID: 84885045627     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3182a80237     Document Type: Article

References (61)

1. Janssen-Heijnen MLG, Schipper RM, Razenberg P, et al. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer. 1998;21:105-113. (Pubitemid 29028028)
2. Brunsvig PF, Kyte JA, Kersten C, et al. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res. 2011;17:6847-6857.
3. Dalyot-Herman N, Bathe OF, Malek TR. Reversal of CD8+ T cell ignorance and induction of anti-tumor immunity by peptide-pulsed APC. J Immunol. 2000;165:6731-6737. (Pubitemid 32001136)
4. Boczkowski D, Nair SK, Snyder D, et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 1996;184:465-472. (Pubitemid 26324100)
5. Chiodoni C, Paglia P, Stoppacciaro A, et al. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J Exp Med. 1999;190:125-134.
6. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179:1109-1118.
7. Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res. 2007;13: 5243-5248. (Pubitemid 47510346)
8. Salgia R, Lynch T, Skarin A, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocytemacrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003;21:624-630. (Pubitemid 46621895)
9. Nemunaitis J, Vorhies J, Pappen B, et al. 10-year follow-up of gene-modified adenoviral-based therapy in 146 non-small-cell lung cancer patients. Cancer Gene Ther. 2007;14:762-763. (Pubitemid 47080358)
10. Nemunaitis J, Sterman D, Jablons D, et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst. 2004;96:326-331. (Pubitemid 38256277)
11. Borrello I, Sotomayor EM, Cooke S, et al. A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum Gene Ther. 1999;10:1983-1991. (Pubitemid 29387912)
12. Nemunaitis J, Jahan T, Ross H, et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther. 2006;13:555-562.
13. Morales JK, Kmieciak M, Knutson KL, et al. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1-bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat. 2010;123:39-49.
14. Serafini P, Carbley R, Noonan KA, et al. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004;64:6337-6343. (Pubitemid 39129439)
15. Morse MA, Hobeika AC, Osada T, et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood. 2008;112:610-618.
16. Nicholaou T, Ebert LM, Davis ID, et al. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res. 2009;15:2166-2173.
17. Chapman PB. Vaccinating patients with autologous tumor. J Clin Oncol. 2002;20:4139-4140. (Pubitemid 35191015)
18. Antonia SJ, Mule J. J.
19. Cella M, Scheidegger D, Palmer-Lehmann K, et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: TT help via APC activation. J Exp Med. 1996;184:747-752. (Pubitemid 26324129)
20. Dessureault S, Alsarraj M, McCarthy S, et al. A GM-CSF/ CD40L producing cell augments anti-tumor T cell responses. J Surg Res. 2005;125:173-181. (Pubitemid 40602390)
21. Dessureault S, Noyes D, Lee D, et al. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM. CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Ann Surg Oncol. 2007;14:869-884. (Pubitemid 46175338)
22. Wroblewski JM, Bixby DL, Borowski C, et al. Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumorassociated antigens. Lung Cancer. 2001;33:181-194. (Pubitemid 32707899)
23. Michael A, Ball G, Quatan N, et al. Delayed disease progression after allogeneic cell vaccination in hormoneresistant prostate cancer and correlation with immunologic variables. Clin Cancer Res. 2005;11:4469-4478. (Pubitemid 40825637)
24. Bercovici N, Haicheur N, Massicard S, et al. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother. 2008;31:101-112. (Pubitemid 351619409)
25. Kusmartsev S, Cheng F, Yu B, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 2003;63:4441-4449. (Pubitemid 36951016)
26. Audia S, Nicolas A, Cathelin D, et al. Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin Exp Immunol. 2007;150:523-530. (Pubitemid 350098743)
27. Phelps RM, Johnson BE, Ihde DC, et al. NCI-navy medical oncology branch cell line data base. J Cell Biochem. 1996;63:32-91.
28. Savage P, Gao L, Vento K, et al. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood. 2004;103:4613-4615. (Pubitemid 38745991)
29. Nagorsen D, Scheibenbogen C, Schaller G, et al. Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients. Int J Cancer. 2003;105:221-225. (Pubitemid 36505325)
30. Minev B, Hipp J, Firat H, et al. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci U S A. 2000;97:4796-4801. (Pubitemid 30238637)
31. Simon R. Optimal two-stage designs for phase II clinical trials. Control. Clin Trials. 1989;10:1-10. (Pubitemid 19099520)
32. Dunn OJ. Multiple comparisons among means. J Am Stat Assoc. 1961;56:52-64.
33. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793-800.
34. Lee S-J, Jang B-C, Lee S-W, et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-ginduced upregulation of B7-H1 (CD274). FEBS Lett. 2006; 580:755-762. (Pubitemid 43152293)
35. Barve M, Bender J, Senzer N, et al. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008;26:4418-4425.
36. Kotsakis A, Vetsika EK, Christou S, et al. Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study. Ann Oncol. 2012;23:442-449.
37. Tuma RS. New response criteria proposed for immunotherapies. J Natl Cancer Inst. 2008;100:1280-1281.
38. Hsieh CL, Chen DS, Hwang LH. Tumor-induced immunosuppression: a barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine. Hum Gene Ther. 2000;11: 681-692.
39. Krug LM, Dao T, Brown AB, et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother. 2010;59:1467-1479.
40. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.
41. van den Eertwegh AJM, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castrationresistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:509-517.
42. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyteassociated antigen 4 in previously vaccinated cancer patients. Proc Nat Acad Sci. 2008;105:3005-3010. (Pubitemid 351723658)
43. Chu Y, Wang LX, Yang G, et al. Efficacy of GM-CSFproducing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma. J Immunother. 2006;29:367-380. (Pubitemid 44288949)
44. Janetzki S, Panageas KS, Ben-Porat L, et al. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother. 2008;57:303-315. (Pubitemid 350295382)
45. Disis ML. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother. 2011;60:433-442.
46. Hamza SA, Mousa SM, Taha SE, et al. Immune response of 23-valent pneumococcal polysaccharide vaccinated elderly and its relation to frailty indices, nutritional status, and serum zinc levels. Geriatr Gerontol Int. 2012;13:223-229.
47. Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49:1373-1379. (Pubitemid 27028925)
48. Disis ML, Schiffman K, Gooley TA, et al. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin Cancer Res. 2000;6:1347-1350. (Pubitemid 30226219)
49. Ló pez MN, Pereda C, Segal G, et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor b-expressing T cells. J Clin Oncol. 2009;27:945-952.
50. Di Rosa F, Pabst R. The bone marrow: a nest for migratory memory T cells. Trends Immunol. 2005;26:360-366. (Pubitemid 40835841)
51. Maziarz RT, Mentzer SJ, Burakoff SJ, et al. Distinct effects of interferon-g and MHC class I surface antigen levels on resistance of the K562 tumor cell line to natural killermediated lysis. Cell Immunol. 1990;130:329-338. (Pubitemid 20368052)
52. Laheru D, Lutz E, Burke J, et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res. 2008;14:1455-1463. (Pubitemid 351413929)
53. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641-648. (Pubitemid 46348738)
54. Zhao J, Cao Y, Lei Z, et al. Selective depletion of CD4+ CD25+ Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res. 2010;70:4850-4858.
55. Mirza N, Fishman M, Fricke I, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006;66:9299-9307. (Pubitemid 44521152)
56. Iclozan C, Antonia S, Chiappori A, et al. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother. 2013;62:909-918.
57. Galluzzi L, Senovilla L, Vacchelli E, et al. Trial watch: dendritic cell-based interventions for cancer therapy. Onco-Immunology. 2012;1:1111-1134.
58. Yamano T, Kaneda Y, Hiramatsu S, et al. Immunity against breast cancer by TERT DNA vaccine primed with chemokine CCL21. Cancer Gene Ther. 2007;14:451-459. (Pubitemid 46588194)
59. Nguyen-Hoai T, Baldenhofer G, Ahmed MSS, et al. CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model. Cancer Gene Ther. 2011; 19:69-76.
60. Vacchelli E, Galluzzi L, Eggermont A, et al. Trial watch: immunostimulatory cytokines. OncoImmunology. 2012;1:493-506.
61. Hall RD, Gray JE, Chiappori AA. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control. 2013;20:22-31.